Interestingly, the AXL-low-expressing tumor cells, which were more sensitive to osimertinib had a higher baseline level of phosphorylated IGF-1R than the AXL-high-expressing tumor cells, suggesting that phosphorylated IGF-1R at baseline level might have less impact on osimertinib sensitivity than AXL expression. Here, IGF1R is linked to neoplasm.